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Abstract: This report describes the trends of chorionic villus sampling (CVS) referred  
for prenatal genetic diagnosis in the past two and a half decades in a Portuguese Center. 
Our cohort of 491 CVS was mostly performed by the transcervical method at the 12th 
gestational week. Data collected within the framework of this study relate to the following: 
sampling method, referral reason versus abnormality and incidence of procedure-related 
pregnancy loss, that declined to about 0.5% over the last 15 years. The year 2000 
represented a change in referral reasons for chorionic tissue collection, shifting from 
almost exclusively for cytogenetic testing to an increasing number of molecular tests for 
monogenic disorders. Herein, success rates as well as cytogenetic and/or molecular DNA 
results are presented. These latter include not only tests for several monogenic disorders, 
but also aneuploidy and maternal cell contamination screening. This retrospective analysis 
reiterates that CVS is a safe and reliable first trimester technique for prenatal diagnosis in 
high genetic risk pregnancies. 
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1. Introduction  
In the early 1980s, unlike the prevailing tendency in other European countries, prenatal testing had 
not been implemented in Portugal. Although the Institute of Medical Genetics (now named Center of 
Medical Genetics, CGM) had the knowhow and the essential equipment to carry out the laboratory 
tests, the Director of the Institute (Doctor Jacinto de Magalhães: 1938–1987), envisaged prenatal 
diagnosis (PND) integrated in a multidisciplinary facility and proposed the establishment of a public 
facility with services of genetic counseling, collection of fetal products, genetic and biochemical 
routine tests and medical termination of pregnancy (the latter carried out in a collaborating central 
Hospital). At that time, however, prenatal practices where considered ethically inappropriate; abortion 
due to genetic causes was not permitted nor was there any legislation concerning this matter. 
Following years of legal, ethical and political disputes, it was in May 1984 that the Portuguese 
government approved a law that “excludes the illicitness of the voluntary termination of pregnancy for 
genetic causes”, enabling the beginning of PND at the CGM. This was a landmark for the progress in 
the fetal diagnosis of genetic disorders in Portugal. Our Center was initially a nationwide service 
provider, but later become essentially regional as further PND facilities were set up in other parts of 
the country [1,2]. 
The continuous clinical implementation of CVS started in 1983, developed by Denis Fairweather and 
Humphrey Ward, of the University College of London, for the diagnosis of the hemoglobinopathies [3,4]. 
CVS worldwide popularity and widest application was attained when chromosomal analysis by  
the direct preparation of tissue was reported, beginning a new era of fetal genetic diagnosis [5].  
Two different approaches were available for chorionic tissue sampling: the transcervical and the 
transabdominal methods. Each method has its own followers but both require trained, coordinated and 
skilled human resources [6,7]. In either case, procedures are performed under ultrasound guidance, 
without any type of anaesthesia and in an ambulatory setting. Irrespective of the sampling method,  
the fetal damage and/or loss directly related to this invasive procedure were the most serious 
complications of CVS [8,9]. It is now consensual that the number of procedure-induced limb defects is 
insignificant if sampling occurs after the 10th week of gestation [10,11]. When opting for an invasive 
procedure, other complications to take into account are twin pregnancies and mosaicism confined to 
the placenta [12,13]. This sampling procedure is performed four to six weeks earlier in gestation, when 
compared to amniocentesis. The relative anticipation of results reduced couple anxiety and allowed 
access to pregnancy termination at a safer gestational time (in some countries pregnancy termination for 
genetic causes was, in the first years, allowed only until the 16th week). CVS was introduced at CGM  
in 1988, on a nationwide basis, performed by trained obstetricians and rapidly became a “must” for 
pregnant women, particularly those with advanced maternal age (AMA) expecting a first child [1,2]. 
In a CVS a small sample of chorionic (placental) tissue is obtained; however, the cells need to be 
further prepared before analysis. Three methods can be used in cytogenetic laboratories: the direct 
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preparation of uncultured cytotrophoblast cells, the short and the long-term culture methods. The latter 
is less prone to false-positive and false-negative results, in addition to providing better quality 
metaphase preparations and is thus preferred for chromosome analysis. Due to the risk of confined 
placental mosaicism, false-positive results can be observed, which has the disadvantage of causing 
anxiety until the final result is obtained [12,14,15]. 
The ease of obtaining DNA from non-cultured villi guided the development of polymerase chain 
reaction (PCR)-based molecular techniques (QF-PCR, quantitative fluorescent PCR) for rapid 
identification of the most frequent aneuploidies [16–18]. Around 2000, in our Center, a multiplex-PCR 
was implemented, using a set of 20 microsatellite markers (short tandem repeats, STR), for the 
screening of common aneuploidies, detection of maternal cell contamination (MCC), fetal sexing and 
zygosity determination, allowing an earlier result in ongoing pregnancies [19]. 
2. Materials and Methods 
This is a retrospective and descriptive study of 491 CVS specimens received in our Center, between 
January 1988 and December 2013, collected in-house or sent from other PND Centers. For the present 
report the authors used private records and the Prenatal Diagnosis Center Annual Activity Reports 
(1987–2007) as well as data in clinical files provided by geneticists/physicians following pregnant 
women in external clinical units (1987–2013). The data was either obtained from publicly available 
records or anonymized before disclosure to researchers, waiving the need for ethic board approval [1,2]. 
Sampling in our Center was performed mostly by the transcervical method (75%) and a satisfactory 
amount of material was obtained on first attempt in 83.8% of cases. The procedure was carried out at  
a mean of 11 weeks plus 3 days (mode = 12 weeks), the earliest case being collected at 6 weeks plus 2 days 
and the latest two at the 17th week of gestation. The age of the pregnant women had a mean of 34 years 
and 4 months, ranging from 17 to 49 years of age. Consanguinity was reported in three couples (0.61%). 
Referrals in the cohort were for risk of a monogenic disorder, advanced maternal age (AMA, 
defined as age 35 years or older), ultrasound abnormality, family history of chromosome abnormality, 
couple anxiety, ultrasound marker and positive biochemical maternal serum screening. In fifty-eight 
cases there was a combination of two reasons for referral. Furthermore, DNA studies were performed 
in clinically selected cases of extreme maternal anxiety, high aneuploidy risk due to a specific 
ultrasound marker or risk for an X-linked disorder. After 2004, all samples with a normal female 
karyotype were analyzed for MCC using STR markers located on chromosomes 13, 18, 21 and X.  
Chromosome Preparations and DNA Extraction 
For both cytogenetic and molecular studies the villi were separated from maternal tissue under an 
inverted microscope and cleaned in an appropriate wash medium. After separation, chromosome 
preparations were obtained by a direct and/or a long-term culture method following previously 
described procedures with slight modifications [20,21]. Metaphases were initially banded using 
trypsin-Giemsa technique, but this was more recently substituted by the Leishman stain. DNA 
extraction and additional studies were done according to standard procedures and disease-specific 
techniques [22]. A blood drop from all pregnant women was also collected onto filter paper, for MCC 
testing and/or further DNA analyses, if required. 
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3. Results and Discussion  
The birth rate in Portugal has decreased drastically over this 26-year period; between 1988 and 
2013 there has been a 30.5% decrease in live-births [23]. In this period a total of 21,304 prenatal 
invasive procedures were processed in our Center, of which 491 (2.3%) were CVS. A comparison  
of the annual CVS and amniocenteses shows a fall in the decade between 1994 and 2003, to less than 
1% CVS per total invasive procedures. This fact is attributed to the introduction of amniofiltration 
(early amniocentesis) and the first trimester ultrasound examination (11–13 weeks), with the offer of 
amniocentesis in case of a positive screen. In contrast, in the last three years CVS represented 
approximately 20% of all invasive procedures (30% in 2012) [1,2]. 
The major drawback of CVS is procedure-related pregnancy loss, with published estimates varying 
between 0.7% and 2% [24]. Even though a quality ultrasound had enabled CVS to attain a high-level 
of efficacy and safety, with the advantage that it can be carried out earlier than amniocentesis (9–13th 
gestational week), procedure-related complications are emphasized to the parents. The rate of CVS-related 
pregnancy loss, defined as fetal loss occurring within 15 days after the procedure, in the first sixteen years 
exceeded by 2.6% that obtained in the last decade. In fact, in the latter period our CVS-related pregnancy 
loss rate has reached values similar to those of amniocentesis (0.5%), although simple comparison of the 
rate of fetal loss after CVS versus amniocentesis does not seem a suitable method for determining the 
procedure-related risk of loss, because CVS is performed earlier in pregnancy. A possible contributing 
factor to the decrease in post-procedure losses is the lower number of attempts needed to obtain a 
satisfactory amount of villi, which in turn is correlated with operators’ experience and skills. Again, in 
the last decade, there was a 12% decrease in the number of cases in which more than one attempt was 
required. There was no recorded case of fetal limb reduction/defects in our cohort. When an 
inconclusive result was obtained women were offered an amniocentesis. In cases referred for a 
monogenic disorder the protocol included karyotyping. 
Overall, the referrals for CVS were comprised of 49.5% for cytogenetic analysis, 50.3% for 
monogenic disorders and 0.2% due to maternal anxiety (non-medical). In our cohort there were 31 
sampling/culture failures (6.3%). Cytogenetic and/or molecular results of the remaining 460 cases are 
presented herein. MCC was observed in 8 of the analyzed samples (1.7%). A summary of the 109 
(23.7%) affected cases and respective maternal age is presented in Table 1. 
Table 1. Number of affected cases among the 460 chorionic villus sampling (CVS). 
N = 109  N (%) Mean Maternal Age ± SD (Range) 
Chromosome abnormality 28 (6.1) 32.0 ± 6.6 (18–45) 
Monogenic disease 81 (17.6) 31.2 ± 4.8 (18–40) 
Data on the annual distribution of referral reasons as well as number and proportion of affected 
cases are shown in Figure 1. In cases with more than one referral reason, only that with the higher 
clinical impact was graphically represented. 
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Figure 1. Annual variability of referral reasons among the 460 CVS. Number of referrals is represented in the Y-axis distributed by years, while the 
second Y-axis represents number of cases where a diagnosis was attained (affected). Percentage of affected cases per year is shown on graphic. 
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In the period under study, average maternal age of our population, at pregnancy, increased from  
27 to 32 years [23]. AMA has currently been dropped as indication for invasive PND; nevertheless, 
maternal age was our main referral until 1997 and according to published studies it is the only 
etiological factor that correlates with frequency of aneuploidies [25]. Among the 28 chromosomal 
abnormalities and the 81 monogenic disorders detected, comparison of maternal age at sampling 
revealed that similar results were observed in the two groups and both are below what was considered 
advanced maternal age (cut-off 35 years), indicating an a priori low risk population (Table 1). Referral 
bias might contribute to this apparent discrepancy, given the fact that our institution specializes in 
genetic diseases and in the beginning of the analyzed time period it was the only health service in the 
country that offered CVS. A large proportion of pregnant women were referred to our Center because 
of a high risk for a genetic disorder, whether previously known from family history or detected  
de novo in the ongoing pregnancy. Especially in more recent years, with increasing availability of 
Prenatal Centers, women with low risk factors (AMA alone) were not usually referred to us. Because 
genetic risks for familial chromosomal anomalies and monogenic disorders are not associated with 
maternal age, this fact probably shifts the median age of women to younger values. Other related 
factors are the small number of samples analyzed and the fact that most women referred for AMA 
alone, mostly had amniocentesis and not CVS. 
The year 2000 represented a shift in referral reasons for CVS collection, moving from almost 
exclusively for cytogenetic testing to an increasing number of molecular tests for monogenic disorders. 
This was mainly attributed to the development and rapid spread of DNA-based methodology. In fact, 
in the decade of 2004–2013 the positivity rate reached on average 40% with a maximum of 55% in 
2010, largely due to genetic diagnosis of monogenic diseases. 
Specific chromosomal analysis referrals consisted of AMA (n = 150), ultrasound abnormality  
(n = 28), family history of chromosome abnormality (n = 22), ultrasound marker (n = 11), positive 
biochemical maternal serum screening (n = 2) and anxiety (n = 1). Normal chromosome results were 
obtained in 187 of 214 cases (87.4%) at risk for a chromosomal aberration. Table 2 summarizes the 
karyotyping results stratified by age and referral reason. 
Type and rate of numerical or structural chromosomal abnormalities found were similar to that of 
several previous studies [25,26]. Numerical anomalies were found in twenty cases and included  
ten trisomy 21, four trisomy 18, four monosomies X, one trisomy 20 and one triploidy. Among the 
patients with a fetus affected with trisomy 21 there were three recurrent situations and two of them 
were from the same woman. Trisomy 20 was observed in one direct culture and was proved to be a 
placenta-confined full trisomy, where a follow-up amniocentesis revealed a normal male karyotype with 
a normal outcome at delivery. Structural rearrangements were observed in eight cases: five inherited 
balanced translocations—t(5;14)mat, t(7;8)mat, t(7;14)pat, rob(15;22)pat, and rob(13;14)mat—the  
latter with a previous fetus with trisomy 13; two derivative chromosomes from parental balanced 
translocations—der(7)t(7;18)pat and der(18)t(18;20)mat—and one ring chromosome—r(21). Among 
the balanced structural anomalies there was a peculiar case of 45,XX,rob(15;22)pat, confirmed  
on follow-up amniocentesis, found in a fetus at risk for familial amyloidotic polyneuropathy  
(affected mother). Two cases of placenta-confined mosaicism were identified in subjects referred for 
monogenic disorders. 
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Table 2. Karyotyping results stratified by age and referral reason. 
N = 215 * in 460 N Age < 35 Age ≥ 35 Mean ± SD (Min–Max) Referral Reason n 
Normal 187 # 61 120 38.5 ± 5.5 (19–49) 
AMA 145 
Ultrasound abnormality 19 
Family history of 
chromosome abnormality 
13 
Ultrasound marker 7 
Positive biochemical 
maternal serum screening 
2 
Anxiety 1 
Abnormal 28 16 12 32.0 ± 6.6 (18–45)   
Trisomy 21 10 4 6 34.6 ± 6.3 (23–42) 
Ultrasound marker 3 
Previous child with  
Down syndrome 
3 
Ultrasound abnormality 2 
AMA 2 
Trisomy 18 4 2 2 33.0 ± 9.3 (23–45) 
Ultrasound abnormality 2 
AMA 1 
Ultrasound marker 1 
Trisomy 20 1 0 1 41 AMA 1 
Monosomy X 4 4 0 29.2 ± 6.5 (18–34) Ultrasound abnormality 4 
Triploidy 1 0 1 37 Ultrasound abnormality 1 
Balanced structural 
rearrangement 
5 4 1 30.9 ± 3.4 (25–35) 
Parent carrier of  
balanced translocation 
4 
* FAP 1 
Unbalanced 
structural 
rearrangement 
3 2 1 31.3 ± 4.0 (28–37) 
Parent carrier of  
balanced translocation 
2 
AMA 1 
# Age unknown in n = 6; * One case that was not referred for chromosomal abnormality. 
Examples of the most frequent disorders screened through molecular studies include familial 
amyloidotic polyneuropathy (FAP, n = 39), Spinal Muscular Atrophy (SMA, n = 18), Fragile-X 
syndrome (FXS, n = 15) and Duchenne muscular dystrophy (DMD, n = 10). This is not surprising 
given that these are relatively frequent genetic disorders in most populations. There is an endemic 
cluster of FAP in the north of Portugal and SMA carrier frequency is also relatively high in  
our population [27–30]. One couple was referred in two consecutive pregnancies for SMA and 
Huntington’s disease (HD); the first fetus was affected with HD and the second, 46,XY was normal for 
both disorders. 
Although dependent on amount of starting material, DNA yield in chorionic villi is higher than  
that obtained from uncultured amniocytes, thereby allowing reliable DNA analysis within hours/days 
of sampling, with the concomitant advantages. With the exception of FXS, nearly all molecularly 
diagnosed disorders were performed on uncultured villi. In eight out of fifteen cases of PND of FXS, 
long-term cultures were needed for methylation-sensitive Southern blot analysis, which is critical for 
distinguishing between a full mutation (expansion with >200 CGGs) responsible for the syndrome 
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itself, and a large premutation (expansion with 56–200 CGGs) responsible for other Fraxopathies. In 
most cases, the sizing of the expansion was sufficient to determine the genotype. However, in two 
cases a subsequent amniocentesis was needed for analysis of the methylation status of the FMR1 
promoter due to a limitation inherent to sample type and timing of sampling: methylation of the full 
mutation is not always completed at the 8–10th week of gestation [31]. These two cases were proven 
to be FMR1 size-mosaics with a premutation and a full mutation. 
When CVS specimens are used directly there is an increased risk of MCC. Although samples 
undergo microscope-guided separation of the maternal deciduas, it is often difficult to eliminate all 
maternal tissue. For this reason, it is important to exclude MCC and be aware that the cells analyzed 
can be potentially different from those analyzed in cultured villi. In fact, in one particular case where 
the tissue was divided for FAP diagnosis and for cytogenetic analysis, both subcultures used for 
chromosome analysis consisted exclusively of maternal cells, while in the fragment used for FAP 
diagnosis MCC was completely excluded. This rare result represents a pitfall, highlighting the need to 
perform MCC exclusion in all aliquots, regardless of the studies they are submitted to. 
Data on MCC is difficult to compare with other studies not only due to limited number of cases but 
also because reports of MCC seem to be based solely on cytogenetic analyses, where numbers are 
reported only when an XY constitution is observed. Because MCC cannot be cytogenetically identified 
in most pregnancies of female fetuses, since 2004 we implemented an STR-based molecular analysis 
for MCC exclusion in cases where disease-specific techniques were unable to detect contamination. 
Besides MCC screening, these analyses were also performed in other specific cases: ultrasound 
observation of a marker for aneuploidy involving chromosomes 13, 18, 21 or X, maternal anxiety or at 
risk pregnancy for an X-linked disorder (for fetal sexing until 2006). Out of the 176 CVS specimens 
received after 2004, sixty-eight cases were analyzed by a multiplex-PCR using a group of 20 STR 
markers, located on chromosomes 13, 18, 21 and X [19]. Results of the aneuploidy molecular screening 
were in accordance with those obtained upon karyotyping (16 normal and 4 affected) and in agreement 
with the expected relative incidence (two cases of monosomy X and two with trisomy 21). 
In a pregnant carrier of a mutation in the MTM1 gene (responsible for X-linked myotubular 
myopathy) fetal sexing was initially done, as a female result would avoid the need for further studies. 
This case, however, was found to be a male fetus hemizygous for the familial MTM1 mutation. This 
case dates back to 2006; more recently, the possibility to perform fetal sexing by non-invasive prenatal 
testing (NIPT) avoids the need for fetal sampling [32]. 
The present study has limitations given that it is retrospective and reports a single-center 
experience, with biased and limited numbers, including follow-up after delivery, thereby hindering 
extrapolation to the national health public system. Nonetheless, it has the advantage of resulting from a 
large number of pregnancies from the same Center, with well-known policy changes over time. 
4. Conclusions 
This retrospective analysis of 491 cases reiterates that CVS has become a safe and reliable choice 
for first trimester prenatal diagnosis in pregnancies at risk for chromosomal abnormality and for 
genetic disorders (with the exception of a few tests such as FXS full mutation detection). These 
conclusions are based on the marked decrease of CVS-related fetal loss and number of attempts 
J. Clin. Med. 2014, 3 846 
 
 
needed for successful sampling, particularly is the last decade. Regarding the laboratory handling of 
the sample, in our experience, it is important that all aliquots of the villi be tested for MCC before 
further studies. 
Although there has been a dramatic decrease in pregnancies/live-births accompanied by an increase 
in maternal age at first conception, this is not reflected in the results reported herein. Over the last 
decade in our Center there was an increase in CVS number and in the proportion of affected cases 
among low-risk chromosomopathy pregnancies (including AMA), mostly due to referral bias. The 
increase in sampling as well as in positivity rate reflects an improvement in referral procedures which 
culminate in a more targeted PND intervention. 
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